Cargando…

IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab

Pemphigus is a life-threatening auto-immune blistering disease of the skin and mucous membrane that is caused by the production of auto-antibodies (auto-Abs) directed against adhesion proteins: desmoglein 1 and 3. We demonstrated in the “Ritux3” trial, the high efficacy of rituximab, an anti-CD20 re...

Descripción completa

Detalles Bibliográficos
Autores principales: Font, Guillaume, Walet-Balieu, Marie-Laure, Petit, Marie, Burel, Carole, Maho-Vaillant, Maud, Hébert, Vivien, Chan, Philippe, Fréret, Manuel, Boyer, Olivier, Joly, Pascal, Calbo, Sébastien, Bardor, Muriel, Golinski, Marie-Laure
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330150/
https://www.ncbi.nlm.nih.gov/pubmed/35892674
http://dx.doi.org/10.3390/biomedicines10081774
_version_ 1784758093103497216
author Font, Guillaume
Walet-Balieu, Marie-Laure
Petit, Marie
Burel, Carole
Maho-Vaillant, Maud
Hébert, Vivien
Chan, Philippe
Fréret, Manuel
Boyer, Olivier
Joly, Pascal
Calbo, Sébastien
Bardor, Muriel
Golinski, Marie-Laure
author_facet Font, Guillaume
Walet-Balieu, Marie-Laure
Petit, Marie
Burel, Carole
Maho-Vaillant, Maud
Hébert, Vivien
Chan, Philippe
Fréret, Manuel
Boyer, Olivier
Joly, Pascal
Calbo, Sébastien
Bardor, Muriel
Golinski, Marie-Laure
author_sort Font, Guillaume
collection PubMed
description Pemphigus is a life-threatening auto-immune blistering disease of the skin and mucous membrane that is caused by the production of auto-antibodies (auto-Abs) directed against adhesion proteins: desmoglein 1 and 3. We demonstrated in the “Ritux3” trial, the high efficacy of rituximab, an anti-CD20 recombinant monoclonal antibody, as the first-line treatment for pemphigus. However, 25% of patients relapsed during the six-month period after rituximab treatment. These early relapses were associated with a lower decrease in anti-desmoglein auto-Abs after the initial cycle of rituximab. The N-glycosylation of immunoglobulin-G (IgG) can affect their affinity for Fc receptors and their serum half-life. We hypothesized that the extended half-life of Abs could be related to modifications of IgG N-glycans. The IgG N-glycome from pemphigus patients and its evolution under rituximab treatment were analyzed. Pemphigus patients presented a different IgG N-glycome than healthy donors, with less galactosylated, sialylated N-glycans, as well as a lower level of N-glycans bearing an additional N-acetylglucosamine. IgG N-glycome from patients who achieved clinical remission was not different to the one observed at baseline. Moreover, our study did not identify the N-glycans profile as discriminating between relapsing and non-relapsing patients. We report that pemphigus patients present a specific IgG N-glycome. The changes observed in these patients could be a biomarker of autoimmunity susceptibility rather than a sign of inflammation.
format Online
Article
Text
id pubmed-9330150
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93301502022-07-29 IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab Font, Guillaume Walet-Balieu, Marie-Laure Petit, Marie Burel, Carole Maho-Vaillant, Maud Hébert, Vivien Chan, Philippe Fréret, Manuel Boyer, Olivier Joly, Pascal Calbo, Sébastien Bardor, Muriel Golinski, Marie-Laure Biomedicines Article Pemphigus is a life-threatening auto-immune blistering disease of the skin and mucous membrane that is caused by the production of auto-antibodies (auto-Abs) directed against adhesion proteins: desmoglein 1 and 3. We demonstrated in the “Ritux3” trial, the high efficacy of rituximab, an anti-CD20 recombinant monoclonal antibody, as the first-line treatment for pemphigus. However, 25% of patients relapsed during the six-month period after rituximab treatment. These early relapses were associated with a lower decrease in anti-desmoglein auto-Abs after the initial cycle of rituximab. The N-glycosylation of immunoglobulin-G (IgG) can affect their affinity for Fc receptors and their serum half-life. We hypothesized that the extended half-life of Abs could be related to modifications of IgG N-glycans. The IgG N-glycome from pemphigus patients and its evolution under rituximab treatment were analyzed. Pemphigus patients presented a different IgG N-glycome than healthy donors, with less galactosylated, sialylated N-glycans, as well as a lower level of N-glycans bearing an additional N-acetylglucosamine. IgG N-glycome from patients who achieved clinical remission was not different to the one observed at baseline. Moreover, our study did not identify the N-glycans profile as discriminating between relapsing and non-relapsing patients. We report that pemphigus patients present a specific IgG N-glycome. The changes observed in these patients could be a biomarker of autoimmunity susceptibility rather than a sign of inflammation. MDPI 2022-07-22 /pmc/articles/PMC9330150/ /pubmed/35892674 http://dx.doi.org/10.3390/biomedicines10081774 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Font, Guillaume
Walet-Balieu, Marie-Laure
Petit, Marie
Burel, Carole
Maho-Vaillant, Maud
Hébert, Vivien
Chan, Philippe
Fréret, Manuel
Boyer, Olivier
Joly, Pascal
Calbo, Sébastien
Bardor, Muriel
Golinski, Marie-Laure
IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab
title IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab
title_full IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab
title_fullStr IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab
title_full_unstemmed IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab
title_short IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab
title_sort igg n-glycosylation from patients with pemphigus treated with rituximab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330150/
https://www.ncbi.nlm.nih.gov/pubmed/35892674
http://dx.doi.org/10.3390/biomedicines10081774
work_keys_str_mv AT fontguillaume iggnglycosylationfrompatientswithpemphigustreatedwithrituximab
AT waletbalieumarielaure iggnglycosylationfrompatientswithpemphigustreatedwithrituximab
AT petitmarie iggnglycosylationfrompatientswithpemphigustreatedwithrituximab
AT burelcarole iggnglycosylationfrompatientswithpemphigustreatedwithrituximab
AT mahovaillantmaud iggnglycosylationfrompatientswithpemphigustreatedwithrituximab
AT hebertvivien iggnglycosylationfrompatientswithpemphigustreatedwithrituximab
AT chanphilippe iggnglycosylationfrompatientswithpemphigustreatedwithrituximab
AT freretmanuel iggnglycosylationfrompatientswithpemphigustreatedwithrituximab
AT boyerolivier iggnglycosylationfrompatientswithpemphigustreatedwithrituximab
AT jolypascal iggnglycosylationfrompatientswithpemphigustreatedwithrituximab
AT calbosebastien iggnglycosylationfrompatientswithpemphigustreatedwithrituximab
AT bardormuriel iggnglycosylationfrompatientswithpemphigustreatedwithrituximab
AT golinskimarielaure iggnglycosylationfrompatientswithpemphigustreatedwithrituximab